Microbial metabolites reduce sbp in patients with resistant hypertension

Access through your institution Buy or subscribe In treatment-naive patients with essential hypertension, supplementation with prebiotic acetylated and butyrylated high-amylose maize starch

(HAMSAB) significantly reduces systolic blood pressure (SBP) as compared with placebo. This finding, from a randomized phase II trial, supports the role of the gut microbiota and its

metabolites (especially acetate and butyrate) in the regulation of blood pressure. In this phase II, double-blinded, cross-over trial, 20 untreated patients with hypertension were randomly

assigned to receive a SCFA-enriched diet (HAMSAB 40 g per day) or placebo. Each patient group received each treatment for 3 weeks, with a 3-week washout period before the cross-over.

Patients who received HAMSAB showed a significant decrease in 24-h SBP compared with baseline levels (_P_ = 0.03), with a placebo-subtracted mean difference of –6.1 mmHg (95% CI –1.4 mmHg to

–10.7 mmHg, _P_ < 0.0001). These changes occurred independently of sex, age and body mass index. Furthermore, the HAMSAB diet shifted the gut microbial composition and increased the

concentration of SCFA-producing commensal microbes. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Access Nature and 54

other Nature Portfolio journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues and

online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes

which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES ORIGINAL ARTICLE *

Jama, H. A. et al. Prebiotic intervention with HAMSAB in untreated essential hypertensive patients assessed in a phase II randomized trial. _Nat. Cardiovasc. Res._

https://doi.org/10.1038/s44161-022-00197-4 (2023) Article  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Nature Reviews Cardiology

http://www.nature.com/nrcardio/ Karina Huynh Authors * Karina Huynh View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence

to Karina Huynh. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Huynh, K. Microbial metabolites reduce SBP in patients with resistant hypertension. _Nat

Rev Cardiol_ 20, 140 (2023). https://doi.org/10.1038/s41569-023-00840-y Download citation * Published: 23 January 2023 * Issue Date: March 2023 * DOI:

https://doi.org/10.1038/s41569-023-00840-y SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative